Form 4: Beta Bionics Director Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Beta Bionics Director Adam Lezack sold 1,406 shares of common stock on October 31, 2025, under a pre-arranged 10b5-1 plan.
Summary
- Adam Lezack, a Director of Beta Bionics, Inc. (BBNX), reported transactions on October 31, 2025.
- Lezack sold a total of 1,406 shares of Beta Bionics Common Stock.
- The sales were executed pursuant to a Rule 10b5-1 Plan adopted on July 31, 2025.
- One transaction involved the sale of 1,368 shares at a weighted average price of $26.8474, with individual prices ranging from $26.27 to $27.24.
- A separate transaction involved the sale of 38 shares at a price of $27.7.
- Following these reported transactions, Adam Lezack directly beneficially owns 9,841 shares of Beta Bionics Common Stock.
Sentiment
Score: 4
Explanation: A director's sale of shares, even under a pre-arranged 10b5-1 plan, can be perceived as a neutral to slightly negative signal, as it represents a reduction in insider ownership, though the pre-planned nature mitigates concerns of opportunistic selling.
Positives
- The reported transactions were conducted under a Rule 10b5-1 Plan, indicating pre-scheduled sales and reducing concerns about opportunistic insider trading.
Negatives
- A director reduced their direct beneficial ownership of the company's common stock by 1,406 shares.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This filing is a routine insider transaction report and does not provide information directly related to broader industry trends or competitors.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Policy Adherence | The transactions were executed pursuant to a Rule 10b5-1 Plan adopted on July 31, 2025, demonstrating adherence to insider trading regulations and corporate governance best practices for pre-planned stock sales. | 07/31/2025 | Mitigates concerns of opportunistic insider trading by ensuring sales are pre-scheduled and not based on material non-public information. |
Stakeholder Impact
- Shareholders: May observe a reduction in director ownership, which could be interpreted neutrally to slightly negatively, although the pre-arranged nature of the 10b5-1 plan lessens the potential for negative sentiment.
Key Dates
| Date | Description |
|---|---|
| 07/31/2025 | Rule 10b5-1 Plan adopted by Adam Lezack. |
| 10/31/2025 | Date of reported stock transactions by Adam Lezack. |
| 11/05/2025 | Date the Form 4 was signed by Stephen Feider, Attorney-in-Fact for Adam Lezack. |
Recommendation
holdThe filing details a routine, pre-planned sale of shares by a director under a Rule 10b5-1 plan. This type of transaction, while reducing insider ownership, does not typically signal a change in the company's fundamental outlook or strategic direction, thus a 'hold' recommendation is appropriate based solely on this report.
Keywords
Beta Bionics, BBNX, Form 4, insider transaction, stock sale, director, Adam Lezack, 10b5-1 plan, equity
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.